Breaking News

Merck KGaA to Acquire Exelead for $780M

Enhances the company's experience in producing lipids, one of the critical components for the formulation of mRNA therapeutics including Covid-19 vaccines.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck KGaA signed a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO), for approximately $780 million in cash. Exelead specializes in complex injectable formulations, including Lipid Nanoparticle (LNP) based drug delivery technology which is key in mRNA therapeutics for use in Covid-19 and many other indications.   “Novel modalities, particularly mRNA, present a highly attractive business opportunity as pharma and biot...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters